Author

H.C. Post

Observed names: H Colinda Post, H. C. Post, H. Colinda Post, Hendrika C. Post

Institutions: Amsterdam UMC Location University of Amsterdam, Cancer Center Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam

Observed institutions: Amsterdam UMC Location University of Amsterdam, Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam

ORCID: 0009-0005-0701-1209

Observed ORCID: 0009-0005-0701-1209

OpenAlex ID: A5061017115

Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries

2023 · H.C. Post, T. Schutte, et al. · ESMO Open · 32

Access to medicines for rare diseases: A European regulatory roadmap for academia

2023 · Noa Rosenberg, Sibren van den Berg, et al. · Frontiers in Pharmacology · 15

Effect of a prediction tool and communication skills training on communication of treatment outcomes: a multicenter stepped wedge clinical trial (the SOURCE trial)

2023 · L.F. van de Water, S.C. Kuijper, et al. · EClinicalMedicine · 8

Access to anticancer and orphan medicines through compassionate use programs and named patient basis in seven European countries

2025 · N. Rosenberg, H.C. Post, et al. · ESMO Open · 3

The narrow road to expanded access

2024 · H.C. Post, T. Schutte, et al. · Journal of Cancer Policy · 2

Painful lower limb nodules as first symptom of resectable pancreatic acinar cell cancer: a case report

2022 · S. M. Haenen, J. A. M. G. Tol, et al. · Journal of Medical Case Reports · 2

Cost implications of early treatment discontinuation in cancer: a real-world data analysis

2026 · H Colinda Post, Kirsten Opmeer, et al. · The Oncologist

Access to EU-Authorized Nonreimbursed Anticancer Medicines: An Explorative Survey Among Dutch Medical Oncologists

2025 · H. Colinda Post, Charlotte H. C． Bomhof, et al. · Clinical Therapeutics

Works count: 8

Citation count: 62

H-index: 3

I10-index: 2